JP2020083787A - Composition for oral cavity - Google Patents
Composition for oral cavity Download PDFInfo
- Publication number
- JP2020083787A JP2020083787A JP2018216224A JP2018216224A JP2020083787A JP 2020083787 A JP2020083787 A JP 2020083787A JP 2018216224 A JP2018216224 A JP 2018216224A JP 2018216224 A JP2018216224 A JP 2018216224A JP 2020083787 A JP2020083787 A JP 2020083787A
- Authority
- JP
- Japan
- Prior art keywords
- betaine
- amphoteric surfactant
- mass
- composition
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 210000000214 mouth Anatomy 0.000 title claims abstract description 20
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 97
- 229960003237 betaine Drugs 0.000 claims abstract description 51
- 239000002280 amphoteric surfactant Substances 0.000 claims abstract description 42
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 29
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 19
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 18
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 18
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract description 18
- 229960004853 betadex Drugs 0.000 claims abstract description 18
- 235000011187 glycerol Nutrition 0.000 claims abstract description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 7
- 239000006185 dispersion Substances 0.000 claims description 4
- 235000019658 bitter taste Nutrition 0.000 abstract description 28
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 abstract 3
- -1 sionel Chemical compound 0.000 description 28
- 235000014113 dietary fatty acids Nutrition 0.000 description 16
- 239000000194 fatty acid Substances 0.000 description 16
- 229930195729 fatty acid Natural products 0.000 description 16
- 239000004094 surface-active agent Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- XPALGXXLALUMLE-UHFFFAOYSA-N 2-(dimethylamino)tetradecanoic acid Chemical compound CCCCCCCCCCCCC(N(C)C)C(O)=O XPALGXXLALUMLE-UHFFFAOYSA-N 0.000 description 4
- YPDCDBRKWQYBPV-UHFFFAOYSA-N 2-[2-(dodecanoylamino)ethyl-(2-hydroxyethyl)amino]acetic acid;sodium Chemical compound [Na].CCCCCCCCCCCC(=O)NCCN(CCO)CC(O)=O YPDCDBRKWQYBPV-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000003899 bactericide agent Substances 0.000 description 4
- 239000007621 bhi medium Substances 0.000 description 4
- 229940096362 cocoamphoacetate Drugs 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006326 Breath odour Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000000551 dentifrice Substances 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 229910001631 strontium chloride Inorganic materials 0.000 description 2
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- ASLICXGLMBICCD-UHFFFAOYSA-N 1-ethyl-4,5-dihydroimidazole Chemical compound CCN1CCN=C1 ASLICXGLMBICCD-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GOHZKUSWWGUUNR-UHFFFAOYSA-N 2-(4,5-dihydroimidazol-1-yl)ethanol Chemical compound OCCN1CCN=C1 GOHZKUSWWGUUNR-UHFFFAOYSA-N 0.000 description 1
- SVIJYLPSHPPVQF-UHFFFAOYSA-N 2-[2,2-diaminoethyl(dodecyl)amino]acetic acid Chemical compound CCCCCCCCCCCCN(CC(N)N)CC(O)=O SVIJYLPSHPPVQF-UHFFFAOYSA-N 0.000 description 1
- HVYJSOSGTDINLW-UHFFFAOYSA-N 2-[dimethyl(octadecyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O HVYJSOSGTDINLW-UHFFFAOYSA-N 0.000 description 1
- HKKXJKUATKEWDT-UHFFFAOYSA-N 2-ethyl-2-(tetradecylamino)butanoic acid Chemical compound C(CCCCCCCCCCCCC)NC(C(=O)O)(CC)CC HKKXJKUATKEWDT-UHFFFAOYSA-N 0.000 description 1
- MUHFRORXWCGZGE-KTKRTIGZSA-N 2-hydroxyethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCO MUHFRORXWCGZGE-KTKRTIGZSA-N 0.000 description 1
- UDWODRKDBDYBRS-UHFFFAOYSA-N 2-methyl-2-(octadecylamino)propanoic acid Chemical compound CCCCCCCCCCCCCCCCCCNC(C)(C)C(O)=O UDWODRKDBDYBRS-UHFFFAOYSA-N 0.000 description 1
- MSHRLZROIXIQJV-UHFFFAOYSA-N 2-methyl-2-(propylamino)propanoic acid Chemical compound CCCNC(C)(C)C(O)=O MSHRLZROIXIQJV-UHFFFAOYSA-N 0.000 description 1
- ZSCYRTQYNJQINM-UHFFFAOYSA-N 2-methyl-2-(tetradecylamino)propanoic acid Chemical compound CCCCCCCCCCCCCCNC(C)(C)C(O)=O ZSCYRTQYNJQINM-UHFFFAOYSA-N 0.000 description 1
- DDGPBVIAYDDWDH-UHFFFAOYSA-N 3-[dodecyl(dimethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC(O)CS([O-])(=O)=O DDGPBVIAYDDWDH-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WHGYBXFWUBPSRW-UHFFFAOYSA-N Cycloheptaamylose Natural products O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO WHGYBXFWUBPSRW-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 description 1
- 108010001682 Dextranase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PTPJTAIOGJWRDA-UHFFFAOYSA-N [Na].C(CCCCCCCCCCC)N(CC(=O)O)CC(N)N.[Na] Chemical compound [Na].C(CCCCCCCCCCC)N(CC(=O)O)CC(N)N.[Na] PTPJTAIOGJWRDA-UHFFFAOYSA-N 0.000 description 1
- GWVPJQDUGPKIOI-UQKRIMTDSA-N [Na].CCCCCCCCCCCC(=O)CN[C@@H](C)C(O)=O Chemical compound [Na].CCCCCCCCCCCC(=O)CN[C@@H](C)C(O)=O GWVPJQDUGPKIOI-UQKRIMTDSA-N 0.000 description 1
- MHZDPHLNZSQJMO-UHFFFAOYSA-N [Na].CCCCCCCCCCCCN(CC(N)N)CC(O)=O Chemical compound [Na].CCCCCCCCCCCCN(CC(N)N)CC(O)=O MHZDPHLNZSQJMO-UHFFFAOYSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940073499 decyl glucoside Drugs 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical class [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- GLSRFBDXBWZNLH-UHFFFAOYSA-L disodium;2-chloroacetate;2-(4,5-dihydroimidazol-1-yl)ethanol;hydroxide Chemical compound [OH-].[Na+].[Na+].[O-]C(=O)CCl.OCCN1CCN=C1 GLSRFBDXBWZNLH-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 108010000165 exo-1,3-alpha-glucanase Proteins 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940074774 glycyrrhizinate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940031957 lauric acid diethanolamide Drugs 0.000 description 1
- 229940094506 lauryl betaine Drugs 0.000 description 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
- 229940048848 lauryl glucoside Drugs 0.000 description 1
- 229940071180 lauryl sulfosuccinate Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007823 ocimene derivatives Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940096501 sodium cocoamphoacetate Drugs 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 229960000414 sodium fluoride Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- HVFAVOFILADWEZ-UHFFFAOYSA-M sodium;2-[2-(dodecanoylamino)ethyl-(2-hydroxyethyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCC(=O)NCCN(CCO)CC([O-])=O HVFAVOFILADWEZ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- FVRNDBHWWSPNOM-UHFFFAOYSA-L strontium fluoride Chemical compound [F-].[F-].[Sr+2] FVRNDBHWWSPNOM-UHFFFAOYSA-L 0.000 description 1
- 229910001637 strontium fluoride Inorganic materials 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- XJPBRODHZKDRCB-UHFFFAOYSA-N trans-alpha-ocimene Natural products CC(=C)CCC=C(C)C=C XJPBRODHZKDRCB-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- VXYADVIJALMOEQ-UHFFFAOYSA-K tris(lactato)aluminium Chemical compound CC(O)C(=O)O[Al](OC(=O)C(C)O)OC(=O)C(C)O VXYADVIJALMOEQ-UHFFFAOYSA-K 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Abstract
Description
本発明は、ベタイン系両性界面活性剤を含有する口腔用組成物に関する。 The present invention relates to an oral composition containing a betaine amphoteric surfactant.
一般に、歯周疾患、歯肉炎、う蝕、口臭等の口腔内疾患は、口腔内細菌によって引き起こされている。口腔内の多くの細菌が、バイオフィルムと呼ばれる細菌の集合体として存在している。バイオフィルムは、細菌又はその死骸、細菌から分泌される多糖、タンパク質等の高分子物質が高分子フィルム状の構造体を有している。そのため、一般的な口腔用組成物に用いられる殺菌剤では、バイオフィルム内へ浸透させることが困難であった。バイオフィルム中の細菌を除去するためには、殺菌剤の浸透性を向上させるか、より効果的には、細菌同士の集合体を物理的又は化学的な方法で分散させて除去することが必要である。例えば、特許文献１は、カチオン性殺菌剤及び両性界面活性剤を含有することにより、カチオン性殺菌剤のバイオフィルムへの浸透性を向上させた殺菌組成物について開示する。特許文献２は、エリスリトール及びＮ−アシル酸性アミノ酸を所定の比率で配合したバイオフィルムを除去するための歯磨組成物について開示する。 In general, oral diseases such as periodontal disease, gingivitis, dental caries and bad breath are caused by oral bacteria. Many bacteria in the oral cavity exist as an aggregate of bacteria called a biofilm. The biofilm has a polymeric film-like structure of a polymeric substance such as a bacterium or a carcass thereof, a polysaccharide secreted from the bacterium, a protein and the like. Therefore, it has been difficult to penetrate into the biofilm with a bactericide used in a general oral composition. In order to remove the bacteria in the biofilm, it is necessary to improve the permeability of the bactericide or, more effectively, disperse and remove the aggregate of the bacteria by a physical or chemical method. Is. For example, Patent Document 1 discloses a bactericidal composition containing a cationic bactericidal agent and an amphoteric surfactant to improve the permeability of the cationic bactericidal agent into a biofilm. Patent Document 2 discloses a dentifrice composition for removing a biofilm containing erythritol and an N-acyl acidic amino acid in a predetermined ratio.
しかしながら、例えばバイオフィルムを分散除去するためにラウリルジメチルアミノ酢酸ベタイン等の特定のベタイン系両性界面活性剤を口腔用組成物に適用した場合、該ベタイン系両性界面活性剤特有の苦味が知覚され、良好な使用感が得られないという問題があった。 However, when a specific betaine amphoteric surfactant such as betaine lauryl dimethylaminoacetic acid betaine is applied to the oral composition in order to disperse and remove the biofilm, for example, the bitterness peculiar to the betaine amphoteric surfactant is perceived, There is a problem that a good usability cannot be obtained.
本発明は、特定のベタイン系両性界面活性剤由来の苦味を低減することができる口腔用組成物を提供することにある。 The present invention is to provide an oral composition capable of reducing bitterness derived from a specific betaine-based amphoteric surfactant.
本発明者らは、前記の課題を解決するべく研究した結果、グリセリン及びβ−シクロデキストリンを併用することにより特定のベタイン系両性界面活性剤由来の苦味を低減することができることを見出したことに基づく発明である。 The present inventors, as a result of research to solve the above problems, found that it is possible to reduce the bitterness derived from a specific betaine amphoteric surfactant by using glycerin and β-cyclodextrin in combination. It is based on the invention.
上記目的を達成するために、本発明の一態様は、炭素数１１以上の炭素鎖を有し、分子中に窒素原子が２つ以下であるベタイン系両性界面活性剤を０．０２質量％以上、グリセリン、及びβ−シクロデキストリンを含有する口腔用組成物が提供される。 In order to achieve the above object, one embodiment of the present invention comprises a betaine-based amphoteric surfactant having a carbon chain of 11 or more carbon atoms and having 2 or less nitrogen atoms in the molecule of 0.02 mass% or more. There is provided an oral composition containing, glycerin, and β-cyclodextrin.
前記ベタイン系両性界面活性剤は、アルキルジメチルアミノ酢酸ベタイン、Ｎ−アルキル−Ｎ’−カルボキシメチル−Ｎ’−ヒドロキシエチルエチレンジアミン塩、及び２−アルキル−Ｎ−カルボキシメチル−Ｎ−ヒドロキシエチルイミダゾリニウムベタインから選ばれる少なくとも１種であってもよい。 The betaine-based amphoteric surfactant includes betaine alkyldimethylaminoacetate, N-alkyl-N'-carboxymethyl-N'-hydroxyethylethylenediamine salt, and 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium. It may be at least one selected from betaine.
前記β−シクロデキストリンの含有量は、０．０１質量％以上であってもよい。
前記ベタイン系両性界面活性剤の含有量は、０．８質量％以下であってもよい。
前記口腔用組成物は、バイオフィルム分散のために用いられてもよい。
The content of β-cyclodextrin may be 0.01% by mass or more.
The content of the betaine-based amphoteric surfactant may be 0.8% by mass or less.
The oral composition may be used for biofilm dispersion.
本発明によれば、苦味を低減することができる。 According to the present invention, bitterness can be reduced.
以下、本発明の口腔用組成物を具体化した一実施形態について説明する。
本実施形態の口腔用組成物は、有用成分として特定の両性界面活性剤を含む。かかる両性界面活性剤としては、特定の炭素鎖及び窒素原子数を有するアルキルベタイン系両性界面活性剤、イミダゾリニウムベタイン系両性界面活性剤等のベタイン系両性界面活性剤が用いられる。より具体的には、本実施形態の口腔用組成物は、有効成分として炭素数１１以上の炭素鎖を有し、分子中に窒素原子が２つ以下であるベタイン系両性界面活性剤を含む。炭素数１１以上の炭素鎖としては、入手容易性の観点からアルキル基であることが好ましい。また、分子中の窒素原子の数としては、対イオンを組成する部分、例えばアンモニウム、アルカノールアミン等に含まれる窒素は除くものとする。かかるベタイン系両性界面活性剤としては例えば、ラウリルベタイン、ステアリルベタイン、アルキルジメチルアミノ酢酸ベタイン、Ｎ−アルキル−Ｎ’−カルボキシメチル−Ｎ’−ヒドロキシエチルエチレンジアミン塩、２−アルキル−Ｎ−カルボキシメチル−Ｎ−ヒドロキシエチルイミダゾリニウムベタイン、ラウリン酸アミドプロピルベタイン、ヤシ油脂肪酸アミドプロピルベタイン、ラウリルヒドロキシスルホベタイン等が挙げられる。これらの成分は、１種のみを適用してもよく、２種以上を組み合わせて適用してもよい。これらの中でもバイオフィルムの分散性に優れている観点からアルキルジメチルアミノ酢酸ベタイン、Ｎ−アルキル−Ｎ’−カルボキシメチル−Ｎ’−ヒドロキシエチルエチレンジアミン塩、２−アルキル−Ｎ−カルボキシメチル−Ｎ−ヒドロキシエチルイミダゾリニウムベタインが好ましい。
Hereinafter, one embodiment which materialized the composition for oral cavity of the present invention is described.
The composition for oral cavity of the present embodiment contains a specific amphoteric surfactant as a useful component. As such an amphoteric surfactant, a betaine-based amphoteric surfactant such as an alkylbetaine-based amphoteric surfactant or an imidazolinium-betaine-based amphoteric surfactant having a specific carbon chain and the number of nitrogen atoms is used. More specifically, the oral composition of the present embodiment contains, as an active ingredient, a betaine-based amphoteric surfactant having a carbon chain of 11 or more carbon atoms and having 2 or less nitrogen atoms in the molecule. The carbon chain having 11 or more carbon atoms is preferably an alkyl group from the viewpoint of easy availability. Further, the number of nitrogen atoms in the molecule excludes nitrogen contained in the counter ion-forming portion, for example, ammonium or alkanolamine. Examples of the betaine-based amphoteric surfactant include lauryl betaine, stearyl betaine, alkyldimethylaminoacetic acid betaine, N-alkyl-N′-carboxymethyl-N′-hydroxyethylethylenediamine salt, 2-alkyl-N-carboxymethyl- Examples thereof include N-hydroxyethylimidazolinium betaine, lauric acid amidopropyl betaine, coconut oil fatty acid amidopropyl betaine, and lauryl hydroxysulfobetaine. These components may be applied alone or in combination of two or more. Among these, alkyldimethylaminoacetic acid betaine, N-alkyl-N′-carboxymethyl-N′-hydroxyethylethylenediamine salt, and 2-alkyl-N-carboxymethyl-N-hydroxy from the viewpoint of excellent biofilm dispersibility. Ethylimidazolinium betaine is preferred.
アルキルジメチルアミノ酢酸ベタインの具体例としては、例えばラウリルジメチルアミノ酢酸ベタイン、ミリスチルジメチルアミノ酢酸ベタイン、ステアリルジメチルアミノ酢酸ベタイン、ヤシ油脂肪酸アミドプロピルジメチルアミノ酢酸ベタイン等が挙げられる。 Specific examples of the alkyl dimethylamino acetic acid betaine include lauryl dimethyl amino acetic acid betaine, myristyl dimethyl amino acetic acid betaine, stearyl dimethyl amino acetic acid betaine, coconut oil fatty acid amide propyl dimethyl amino acetic acid betaine and the like.
Ｎ−アルキル−Ｎ’−カルボキシメチル−Ｎ’−ヒドロキシエチルエチレンジアミン塩の具体例としては、例えばＮ−ラウロイル−Ｎ’−カルボキシメチル−Ｎ’−ヒドロキシエチルエチレンジアミンナトリウム、Ｎ−ヤシ油脂肪酸アシル−Ｎ’−カルボキシエチル−Ｎ’−ヒドロキシエチルエチレンジアミンナトリウム（ココアンホプロピオン酸Ｎａ）等が挙げられる。 Specific examples of the N-alkyl-N′-carboxymethyl-N′-hydroxyethylethylenediamine salt include, for example, N-lauroyl-N′-carboxymethyl-N′-hydroxyethylethylenediamine sodium salt and N-coconut oil fatty acid acyl-N. Examples include'-carboxyethyl-N'-hydroxyethylethylenediamine sodium (Na cocoamphopropionate) and the like.
２−アルキル−Ｎ−カルボキシメチル−Ｎ−ヒドロキシエチルイミダゾリニウムベタインの具体例としては、例えばココアンホ酢酸Ｎａ等が挙げられる。
上述した成分は、市販品を使用してもよく、ラウリルジメチルアミノ酢酸ベタインとしては、例えばＮＩＫＫＯＬ ＡＭ−３０１（日光ケミカルズ社製）、アンヒトール２０ＢＳ（花王社製）、リカビオンＡ−１００（新日本理化社製）等が挙げられる。Ｎ−ラウロイル−Ｎ’−カルボキシメチル−Ｎ’−ヒドロキシエチルエチレンジアミンナトリウムとしては、例えばソフタゾリンＬＨＬ（川研ファインケミカル社製）、ソフタゾリンＬＨＬ−ＳＦ（川研ファインケミカル社製）、レボン１０１−Ｈ（三洋化成工業社製）等が挙げられる。ココアンホ酢酸Ｎａとしては、ＮＩＫＫＯＬ ＡＭ−１０１（日光ケミカルズ社製）、ニッサンアノンＧＬＭ−Ｒ−ＬＶ（日油社製）、ソフタゾリンＣＬ（川研ファインケミカル社製）等が挙げられる。
Specific examples of 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine include Na cocoamphoacetate and the like.
As the above-mentioned components, commercially available products may be used, and examples of lauryldimethylaminoacetic acid betaine include NIKKOL AM-301 (manufactured by Nikko Chemicals), Amphitol 20BS (manufactured by Kao), and Rikabion A-100 (Shin Nippon Rika). Manufactured by the company) and the like. Examples of N-lauroyl-N'-carboxymethyl-N'-hydroxyethylethylenediamine sodium include, for example, softofazoline LHL (manufactured by Kawaken Fine Chemicals Co., Ltd.), softazoline LHL-SF (manufactured by Kawaken Fine Chemicals Co., Ltd.), Levon 101-H (Sanyo Kasei Co., Ltd.). (Manufactured by Kogyo Co., Ltd.) and the like. Examples of Na cocoamphoacetate include NIKKOL AM-101 (manufactured by Nikko Chemicals Co., Ltd.), Nissan Anon GLM-R-LV (manufactured by NOF CORPORATION), and softazoline CL (manufactured by Kawaken Fine Chemicals Co., Ltd.).
いずれの成分も上記具体例に限ったものではない。これらの具体例の中でもバイオフィルムの分散性に優れる観点からＮ−ラウロイル−Ｎ’−カルボキシメチル−Ｎ’−ヒドロキシエチルエチレンジアミンナトリウム、ココアンホ酢酸Ｎａが好ましい。 Neither component is limited to the above specific examples. Among these specific examples, N-lauroyl-N'-carboxymethyl-N'-hydroxyethylethylenediamine sodium and cocoamphoacetate Na are preferable from the viewpoint of excellent dispersibility of biofilm.
口腔用組成物中における上述したベタイン系両性界面活性剤の含有量の下限は、０．０２質量％以上、好ましくは０．０５質量％以上、より好ましくは０．１質量％以上である。尚、成分の含有量を示す質量％の数値は、水、アルコール等の基剤も含めた組成物中における数値である（以下、同じ）。上述したベタイン系両性界面活性剤の含有量が０．０２質量％以上の場合、グリセリン及びβ−シクロデキストリンを併用した場合における苦味の低減効果を実感することができる。また、上述したベタイン系両性界面活性剤の有効成分としての効能を効果的に発揮することができる。 The lower limit of the content of the above betaine-based amphoteric surfactant in the oral composition is 0.02% by mass or more, preferably 0.05% by mass or more, and more preferably 0.1% by mass or more. In addition, the numerical value of mass% showing the content of the component is the numerical value in the composition including the base such as water and alcohol (hereinafter the same). When the content of the above-mentioned betaine-based amphoteric surfactant is 0.02% by mass or more, the effect of reducing bitterness when glycerin and β-cyclodextrin are used in combination can be realized. Further, the effects of the above betaine-based amphoteric surfactant as an active ingredient can be effectively exhibited.
口腔用組成物中における上述したベタイン系両性界面活性剤の含有量の上限は、特に限定されないが、好ましくは０．８質量％以下、より好ましくは０．５質量％以下である。上述したベタイン系両性界面活性剤の含有量が０．８質量％以下の場合、グリセリン及びβ−シクロデキストリンを併用した場合における苦味の低減効果をより効果的に発揮することができる。 The upper limit of the content of the above betaine-based amphoteric surfactant in the oral composition is not particularly limited, but is preferably 0.8% by mass or less, more preferably 0.5% by mass or less. When the content of the above betaine-based amphoteric surfactant is 0.8% by mass or less, the bitterness-reducing effect when glycerin and β-cyclodextrin are used in combination can be more effectively exhibited.
口腔用組成物は、上述したベタイン系両性界面活性剤由来の苦味を低減するために、グリセリン及びβ−シクロデキストリンを含有する。グリセリンは、特に含嗽時の苦味を低減させる。口腔用組成物中におけるグリセリンの含有量の下限は、特に限定されないが、好ましくは０．１質量％以上、より好ましくは０．５質量％以上、さらに好ましくは１質量％以上である。一方、グリセリンの含有量の上限は、特に限定されないが、好ましくは２５質量％以下、より好ましくは２０質量％以下、さらに好ましくは１５質量％以下である。かかる範囲に規定することにより、本発明の効果をより効率的に向上させる。また、組成物の物性をより安定化させる。 The composition for oral cavity contains glycerin and β-cyclodextrin in order to reduce the bitterness derived from the above-mentioned betaine-based amphoteric surfactant. Glycerin reduces bitterness, especially when gargles. The lower limit of the content of glycerin in the oral composition is not particularly limited, but is preferably 0.1% by mass or more, more preferably 0.5% by mass or more, and further preferably 1% by mass or more. On the other hand, the upper limit of the glycerin content is not particularly limited, but is preferably 25% by mass or less, more preferably 20% by mass or less, and further preferably 15% by mass or less. By defining the content in such a range, the effect of the present invention is more efficiently improved. In addition, the physical properties of the composition are further stabilized.
β−シクロデキストリンは、シクロヘプタアミロースとも呼ばれグルコースが７個結合した構造を有する。β−シクロデキストリンは、特に後味の苦味を低減させる。口腔用組成物中におけるβ−シクロデキストリンの含有量の下限は、特に限定されないが、好ましくは０．０１質量％以上、より好ましくは０．０３質量％以上、さらに好ましくは０．０５質量％以上である。一方、β−シクロデキストリンの含有量の上限は、特に限定されないが、好ましくは５質量％以下、より好ましくは１質量％以下、さらに好ましくは０．５質量％以下である。かかる範囲に規定することにより、本発明の効果をより効率的に向上させる。 β-Cyclodextrin is also called cycloheptaamylose and has a structure in which seven glucoses are bound. β-Cyclodextrin reduces bitterness, especially aftertaste. The lower limit of the content of β-cyclodextrin in the composition for oral cavity is not particularly limited, but preferably 0.01% by mass or more, more preferably 0.03% by mass or more, further preferably 0.05% by mass or more. Is. On the other hand, the upper limit of the β-cyclodextrin content is not particularly limited, but is preferably 5% by mass or less, more preferably 1% by mass or less, and further preferably 0.5% by mass or less. By defining the content in such a range, the effect of the present invention is more efficiently improved.
口腔用組成物の適用目的は、特に限定されず、有効成分がベタイン系両性界面活性剤である観点から、かかる有効成分の効能を発揮するための組成物、例えばバイオフィルムへの殺菌剤の浸透性を向上させた殺菌用組成物、バイオフィルムを分散除去するためのバイオフィルム分散用組成物等が挙げられる。これらの中で、上述したベタイン系両性界面活性剤を有効成分とするのみで優れたバイオフィルム分散効果を発揮する観点からバイオフィルム分散用組成物として適用することが好ましい。 The application purpose of the oral composition is not particularly limited, from the viewpoint that the active ingredient is a betaine-based amphoteric surfactant, a composition for exhibiting the effects of such active ingredient, for example, penetration of a biocide into a biofilm. Examples thereof include a sterilizing composition having improved properties, a biofilm-dispersing composition for dispersing and removing a biofilm, and the like. Among these, it is preferable to apply the composition as a biofilm dispersion composition from the viewpoint of exhibiting an excellent biofilm dispersion effect only by using the above-mentioned betaine-based amphoteric surfactant as an active ingredient.
口腔用組成物の適用形態は、特に限定されず、例えば医薬品、医薬部外品として使用することができる。口腔用組成物の用途としては、公知のものを適宜採用することができ、例えば練歯磨剤、洗口剤、含漱剤、液体歯磨剤、バイオフィルム分散剤、口臭予防剤、歯茎マッサージ剤、口腔用湿潤付与剤、舌苔除去剤、口腔内塗布剤、口腔殺菌剤、咽喉殺菌剤、口腔咽喉剤、歯周病治療剤、義歯装着剤、義歯コーティング剤、義歯安定化剤、義歯保存剤、義歯洗浄剤、インプラントケア剤等が挙げられる。また、剤型は特に限定されるものではないが、例えば水、アルコール等の基剤を含有することにより、軟膏剤、ペースト剤、パスタ剤、スプレー剤、ジェル剤、液剤、懸濁・乳化剤、ガム剤等に適用することができる。 The application form of the composition for oral cavity is not particularly limited, and it can be used, for example, as a medicine or a quasi drug. As the use of the composition for oral cavity, known ones can be appropriately adopted, for example, toothpaste, mouthwash, mouthwash, liquid dentifrice, biofilm dispersant, breath odor preventive agent, gum massage agent, Oral moisturizer, tongue coating remover, oral application agent, oral disinfectant, throat disinfectant, oropharyngeal agent, periodontal treatment agent, denture mounting agent, denture coating agent, denture stabilizer, denture preservative, Examples include denture cleansing agents and implant care agents. Further, the dosage form is not particularly limited, for example, by containing a base such as water, alcohol, ointment, paste, pasta, spray, gel, liquid, suspension/emulsifier, It can be applied to gums and the like.
口腔用組成物は、適用目的、形態、用途等に応じて、前述した成分以外の成分、例えば抗菌剤、抗炎症剤、香料、上記以外の湿潤剤、上記以外の界面活性剤、研磨剤、アルコール類、増粘剤、甘味成分、薬用成分、安定剤、ｐＨ調整剤等を配合してもよい。これら各成分は、口腔用組成物に配合される公知のものを使用することができる。これらの成分は、それぞれ１種のみを適用してもよく、２種以上を組み合わせて適用してもよい。 Oral composition, depending on the application purpose, form, use, etc., components other than the components described above, such as antibacterial agents, anti-inflammatory agents, fragrances, wetting agents other than the above, surfactants other than the above, abrasives, You may mix|blend alcohols, a thickener, a sweetening component, a medicinal component, a stabilizer, a pH adjuster, etc. As each of these components, known components to be incorporated into the composition for oral cavity can be used. Each of these components may be applied alone or in combination of two or more.
抗菌剤の具体例として、例えば塩化セチルピリジニウム、パラベン、安息香酸ナトリウム、トリクロサン、塩酸クロルヘキシジン、イソプロピルメチルフェノール、塩化ベンザルコニウム、塩化ベンゼトニウム等が挙げられる。抗炎症剤の具体例として、例えばグリチルリチン酸塩、トラネキサム酸、ε−アミノカプロン酸、オウバクエキス等が挙げられる。 Specific examples of the antibacterial agent include cetylpyridinium chloride, paraben, sodium benzoate, triclosan, chlorhexidine hydrochloride, isopropylmethylphenol, benzalkonium chloride, benzethonium chloride and the like. Specific examples of the anti-inflammatory agent include glycyrrhizinate, tranexamic acid, ε-aminocaproic acid, and oat extract.
香料の具体例として、例えばアネトール、オイゲノール、リナロール、メントール、カルボン、リモネン、ウインターグリーン、サリチル酸メチル、シオネール、チモール、丁字油、ユーカリ油、ローズマリー油、セージ油、レモン油、オレンジ油、オシメン油、シトロネロール、各種香料の水溶性香料等が挙げられる。 Specific examples of the fragrance include, for example, anethole, eugenol, linalool, menthol, carvone, limonene, wintergreen, methyl salicylate, sionel, thymol, clove oil, eucalyptus oil, rosemary oil, sage oil, lemon oil, orange oil, ocimene oil. , Citronellol, water-soluble flavors of various flavors, and the like.
湿潤剤の具体例としては、例えばソルビット、エチレングリコール、プロピレングリコール、１，３−ブリレングリコール、ポリエチレングリコール等の多価アルコール等が挙げられる。 Specific examples of the wetting agent include polyhydric alcohols such as sorbit, ethylene glycol, propylene glycol, 1,3-brylene glycol, and polyethylene glycol.
界面活性剤の具体例としては、例えば非イオン性界面活性剤、アニオン界面活性剤、上記以外の両性界面活性剤が挙げられる。非イオン性界面活性剤の具体例としては、例えばショ糖脂肪酸エステル、マルトース脂肪酸エステル等の糖脂肪酸エステル、マルチトール脂肪酸エステル等の糖アルコール脂肪酸エステル、モノラウリン酸ソルビタン等のソルビタン脂肪酸エステル、ポリオキシエチレンソルビタンモノラウレート、ポリオキシエチレンソルビタンモノステアレート等のポリオキシエチレンソルビタン脂肪酸エステル、ラウリン酸ジエタノールアミド等の脂肪酸アルカノールアミド、ポリオキシエチレンステアリルエーテル、ポリオキシエチレンオレイルエーテル等のポリオキシエチレンアルキルエーテル、モノオレイン酸ポリエチレングリコール、モノラウリン酸ポリエチレングリコール等のポリエチレングリコール脂肪酸エステル、ラウリルグルコシド、デシルグルコシド等のアルキルグルコシド、ポリグリセリン脂肪酸エステル、ポリオキシエチレングリセリン脂肪酸エステル、ポリオキシエチレン脂肪酸エステル、アルキルグルコシド類、ポリオキシエチレン硬化ヒマシ油、グリセリン脂肪酸エステル、ポリオキシエチレンプロピレンブロックコポリマー等が挙げられる。 Specific examples of the surfactant include, for example, nonionic surfactants, anionic surfactants, and amphoteric surfactants other than the above. Specific examples of the nonionic surfactant include sugar fatty acid esters such as sucrose fatty acid ester and maltose fatty acid ester, sugar alcohol fatty acid ester such as maltitol fatty acid ester, sorbitan fatty acid ester such as sorbitan monolaurate, and polyoxyethylene. Sorbitan monolaurate, polyoxyethylene sorbitan fatty acid ester such as polyoxyethylene sorbitan monostearate, fatty acid alkanolamide such as lauric acid diethanolamide, polyoxyethylene stearyl ether, polyoxyethylene alkyl ether such as polyoxyethylene oleyl ether, Polyethylene glycol monooleate, polyethylene glycol fatty acid ester such as polyethylene glycol monolaurate, lauryl glucoside, alkyl glucoside such as decyl glucoside, polyglycerin fatty acid ester, polyoxyethylene glycerin fatty acid ester, polyoxyethylene fatty acid ester, alkyl glucosides, poly Examples include oxyethylene hydrogenated castor oil, glycerin fatty acid ester, polyoxyethylene propylene block copolymer, and the like.
また、アニオン界面活性剤の具体例としては、例えばラウリル硫酸ナトリウム、ポリオキシエチレンラウリルエーテル硫酸ナトリウム等の硫酸エステル塩、ラウリルスルホコハク酸ナトリウム、ポリオキシエチレンラウリルエーテルスルホコハク酸ナトリウム等のスルホコハク酸塩、ココイルサルコシンナトリウム、ラウロイルメチルアラニンナトリウム等のアシルアミノ酸塩、ココイルメチルタウリンナトリウム等が挙げられる。 Specific examples of the anionic surfactant include, for example, sodium lauryl sulfate, sulfate ester salts such as sodium polyoxyethylene lauryl ether sulfate, sodium lauryl sulfosuccinate, sulfosuccinate salts such as sodium polyoxyethylene lauryl ether sulfosuccinate, and cocoyl. Examples thereof include acyl amino acid salts such as sodium sarcosine and sodium lauroylmethylalanine, and sodium cocoylmethyl taurine.
また、両性界面活性剤の具体例としては、例えばＮーラウリルジアミノエチルグリシン、Ｎーミリスチルジエチルグリシン等のアミノ酸型両性界面活性剤等が挙げられる。
研磨剤としては、例えば炭酸カルシウム、炭酸マグネシウム、第二リン酸カルシウム、第三リン酸カルシウム、リン酸マグネシウム、シリカ、ゼオライト、メタリン酸ナトリウム、水酸化アルミニウム、水酸化マグネシウム、ピロリン酸カルシウム、ベンガラ、硫酸カルシウム、無水ケイ酸等が挙げられる。アルコール類の具体例としては、例えばエチルアルコール、ラウリルアルコール、ミリスチルアルコール等が挙げられる。
Further, specific examples of the amphoteric surfactant include amino acid type amphoteric surfactants such as N-lauryldiaminoethylglycine and N-myristyldiethylglycine.
Examples of the abrasive include calcium carbonate, magnesium carbonate, dibasic calcium phosphate, tricalcium phosphate, magnesium phosphate, silica, zeolite, sodium metaphosphate, aluminum hydroxide, magnesium hydroxide, calcium pyrophosphate, red iron oxide, calcium sulfate, and anhydrous silica. Acid etc. are mentioned. Specific examples of alcohols include ethyl alcohol, lauryl alcohol, myristyl alcohol and the like.
増粘剤の具体例としては、例えばポリアクリル酸ナトリウム、カラギーナン、カルボキシメチルセルロースナトリウム、アルギン酸ナトリウム、キサンタンガム、ヒドロキシエチルセルロース、ヒドロキシプロピルメチルセルロース、メチルセルロース、アルギン酸プロピレングリコールエステル等が挙げられる。甘味成分の具体例としては、例えばサッカリン、サッカリンナトリウム、スクラロース、ステビオサイド、アセスルファムカム、アスパルテーム、キシリトール、マルチトール、エリスリトール等が挙げられる。 Specific examples of the thickener include sodium polyacrylate, carrageenan, sodium carboxymethyl cellulose, sodium alginate, xanthan gum, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, propylene glycol alginate and the like. Specific examples of the sweetening component include saccharin, saccharin sodium, sucralose, stevioside, acesulfamecum, aspartame, xylitol, maltitol, erythritol and the like.
薬用成分の具体例としては、例えばモノフルオロリン酸ナトリウム、フッ化ナトリウム、フッ化第１スズ、フッ化ストロンチウム等のフッ化物、ピロリン酸ナトリウムやポリリン酸ナトリウム等の縮合リン酸塩、リン酸一水素ナトリウム、リン酸三ナトリウム等のリン酸塩、アスコルビン酸、アスコルビン酸ナトリウム、塩酸ピリドキシン、トコフェロール酢酸エステル等のビタミン剤、デキストラナーゼ、ムタナーゼ等のグルカナーゼ酵素、プロテアーゼ、リゾチーム等の分解酵素、塩化亜鉛、クエン酸亜鉛、塩化ストロンチウム、硝酸カリウム等の無機塩類、クロロフィル、グリセロホスフェート等のキレート性化合物、脂を溶解するポリエチレングリコール等、塩化ナトリウム、乳酸アルミニウム、塩化ストロンチウム等が挙げられる。 Specific examples of the medicinal component include, for example, fluorides such as sodium monofluorophosphate, sodium fluoride, stannous fluoride and strontium fluoride, condensed phosphates such as sodium pyrophosphate and sodium polyphosphate, and monophosphate. Sodium hydrogen, phosphates such as trisodium phosphate, ascorbic acid, sodium ascorbate, pyridoxine hydrochloride, vitamin agents such as tocopherol acetate, glucanase enzymes such as dextranase and mutanase, degrading enzymes such as protease and lysozyme, chloride Examples thereof include inorganic salts such as zinc, zinc citrate, strontium chloride and potassium nitrate, chelating compounds such as chlorophyll and glycerophosphate, polyethylene glycol which dissolves fat, sodium chloride, aluminum lactate, strontium chloride and the like.
安定剤の具体例としては、例えば緑色１号、青色１号、黄色４号等の法定色素、酸化チタン等が挙げられる。ｐＨ調整剤の具体例としては、例えばクエン酸、リンゴ酸、乳酸、酒石酸、酢酸、リン酸、ピロリン酸、グリセロリン酸、並びにこれらのカリウム塩、ナトリウム塩及びアンモニウム塩等の各種塩、水酸化ナトリウム等が挙げられる。口腔用組成物は、ｐＨ調整剤を配合することにより、ｐＨが５〜９、特に６〜８の範囲になるように調整されていることが好ましい。 Specific examples of the stabilizer include legal dyes such as Green No. 1, Blue No. 1, Yellow No. 4 and titanium oxide. Specific examples of the pH adjusting agent include, for example, citric acid, malic acid, lactic acid, tartaric acid, acetic acid, phosphoric acid, pyrophosphoric acid, glycerophosphoric acid, and various salts thereof such as potassium salt, sodium salt and ammonium salt, sodium hydroxide. Etc. It is preferable that the composition for oral cavity is adjusted to have a pH in the range of 5 to 9, particularly 6 to 8 by adding a pH adjusting agent.
本実施形態の口腔用組成物によれば、以下のような効果を得ることができる。
（１）本実施形態の口腔用組成物では、有効成分として炭素数１１以上の炭素鎖を有し、分子中に窒素原子が２つ以下であるベタイン系両性界面活性剤を０．０２質量％以上含有している。かかる構成において、グリセリン及びβ−シクロデキストリンを配合した。したがって、優れたベタイン系両性界面活性剤由来の苦味を低減する効果を発揮できる。
According to the composition for oral cavity of the present embodiment, the following effects can be obtained.
(1) In the oral composition of the present embodiment, 0.02% by mass of a betaine-based amphoteric surfactant having a carbon chain of 11 or more carbon atoms as an active ingredient and having 2 or less nitrogen atoms in the molecule. It contains above. In such a configuration, glycerin and β-cyclodextrin were blended. Therefore, the effect of reducing the bitterness derived from the excellent betaine amphoteric surfactant can be exhibited.
（２）有効成分として炭素数１１以上の炭素鎖を有し、分子中に窒素原子が２つ以下であるベタイン系両性界面活性剤は、単独でも高いバイオフィルム除去能を発揮することができる。 (2) A betaine-based amphoteric surfactant having a carbon chain of 11 or more carbon atoms as an active ingredient and having 2 or less nitrogen atoms in the molecule can exhibit high biofilm removing ability alone.
なお、上記実施形態は以下のように変更してもよい。
・上記実施形態において上述した両性界面活性剤、グリセリン、及びβ−シクロデキストリンは、使用時に口腔用組成物中に配合されていればよく、保存時において口腔用組成物を構成する成分を複数剤に分けて保存してもよい。また、口腔用組成物を粉末等の固体状の剤として保存し、使用時に水等の基剤を加えて使用するように構成してもよい。かかる構成においても、優れた上記ベタイン系両性界面活性剤由来の苦味を低減する効果を発揮できる。
The above embodiment may be modified as follows.
-The amphoteric surfactant, glycerin, and β-cyclodextrin described above in the above embodiment may be incorporated in the oral composition at the time of use, and a plurality of components constituting the oral composition at the time of storage may be used. It may be divided and stored. Further, the oral composition may be stored as a solid agent such as powder, and a base such as water may be added before use. Even in such a constitution, the effect of reducing the bitterness derived from the excellent betaine-based amphoteric surfactant can be exhibited.
本発明の口腔用組成物について、以下の試験例に基づいてさらに詳細に説明する。なお、本発明は、実施例欄記載の構成に限定されるものではない。
＜参考試験：バイオフィルム分散能の試験＞
まず、下記表１に示される各界面活性剤を用いて各成分単独でバイオフィルムの分散能を有するか否かについて試験した。また、併せて各界面活性剤を含有する水溶液について苦味を評価した。なお、表２における各成分を示す欄中の数値は、当該成分の含有量を示し、その単位は質量％である。
The oral composition of the present invention will be described in more detail based on the following test examples. The present invention is not limited to the configuration described in the example section.
<Reference test: biofilm dispersibility test>
First, each of the surfactants shown in Table 1 below was used to test whether or not each component alone had the biofilm dispersibility. In addition, the bitterness of the aqueous solution containing each surfactant was also evaluated. In addition, the numerical value in the column showing each component in Table 2 shows the content of the said component, and the unit is mass %.
まず、表１に示される各界面活性剤を表２に示される含有量で水に溶解した。得られた各水溶液について、下記の試験方法にてバイオフィルムの残存率（％）及び口に含んだ際の苦味について評価した。結果を表２に示す。 First, each of the surfactants shown in Table 1 was dissolved in water with the content shown in Table 2. Each of the obtained aqueous solutions was evaluated for residual rate (%) of biofilm and bitterness when contained in the mouth by the following test methods. The results are shown in Table 2.
（バイオフィルム残存率の測定）
（１）不活化PBSの調製
１Ｌの蒸留水にPBSの錠剤を１０粒、レシチン粉末０．７ｇ、Tween５ｇを加え、ホットスターラーで撹拌しながらTween80を添加して完全に溶解した後に、１２１℃、２０分でオートクレーブ滅菌して調製した。
(Measurement of biofilm residual rate)
(1) Preparation of inactivated PBS Ten tablets of PBS, 0.7 g of lecithin powder, and 5 g of Tween were added to 1 L of distilled water, and Tween80 was added to the mixture while stirring with a hot stirrer to completely dissolve the mixture. It was prepared by autoclave sterilization in 20 minutes.
（２）培地の調製及びバイオフィルムの形成
（ａ）Brain Heart Infusion Broth（BHI）培地及び０．５％（ｗ/ｖ）スクロース入りBHI培地の調製
蒸留水１ＬにBHI３７ｇ、スクロース入りの場合はさらにスクロース５ｇを加えて撹拌し、１２１℃、２０分でオートクレーブ滅菌して調製した。
(2) Preparation of medium and formation of biofilm (a) Preparation of Brain Heart Infusion Broth (BHI) medium and BHI medium containing 0.5% (w/v) sucrose 37 g of BHI in 1 L of distilled water, and further in the case of containing sucrose 5 g of sucrose was added, stirred, and autoclaved at 121° C. for 20 minutes for sterilization.
（ｂ）Streptococcus mutansバイオフィルムの形成
BHI寒天培地上のS. mutans（ATCC25175）をプラスチックの白金耳でかきとり５０ｍＬチューブ中の１０ｍＬのBHI培地に植菌し、３７℃で２４時間アネロパック・ケンキ（三菱ガス化学社製）を用いて嫌気培養し、前培養液とした。
(B) Formation of Streptococcus mutans biofilm
S. mutans (ATCC25175) on BHI agar medium is scraped off with a plastic platinum loop to inoculate 10 mL of BHI medium in a 50 mL tube, and anaerobically using Aneropack Kenki (Mitsubishi Gas Chemical Co., Ltd.) for 24 hours at 37°C. The cells were cultured and used as a preculture liquid.
前培養液を５０ｍＬファルコンチューブ中の１０ｍＬのBHI培地に１/１００となるように植菌し、前培養と同様の方法で１８時間培養し、本培養液とした。
本培養液の濁度がOD600＝０．０５となるように０．５％（ｗ/ｖ）スクロース入りBHI培地で希釈し、９６ウェルプレートに１５０μＬずつ分注した。３７℃で約２４時間嫌気培養し、バイオフィルムを形成した。
The preculture liquid was inoculated into 10 mL of BHI medium in a 50 mL Falcon tube at a ratio of 1/100, and cultured for 18 hours in the same manner as in the preculture to obtain a main culture liquid.
The main culture solution was diluted with BHI medium containing 0.5% (w/v) sucrose so that the turbidity of the main culture solution would be OD 600 =0.05, and 150 μL of the solution was dispensed into a 96-well plate. Anaerobic culture was performed at 37° C. for about 24 hours to form a biofilm.
（３）界面活性剤の調製
表１に示される各界面活性剤を表２に示される含有量となるようにビーカーの中の８０ｍＬの１０％DMSOに添加し、マグネチックスターラーで撹拌しながら１Ｎ塩酸又は１Ｎ水酸化ナトリウムを用いてｐＨを７に調整した。溶液をメスフラスコに移し、１０％DMSOで１００ｍＬにメスアップして各参考例の界面活性剤溶液を調製した。
(3) Preparation of Surfactant Each of the surfactants shown in Table 1 was added to 80 mL of 10% DMSO in a beaker so as to have the content shown in Table 2, and stirred with a magnetic stirrer to give 1N. The pH was adjusted to 7 with hydrochloric acid or 1N sodium hydroxide. The solution was transferred to a volumetric flask, and the volume was adjusted to 100 mL with 10% DMSO to prepare the surfactant solution of each reference example.
（４）薬剤処理
形成したバイオフィルムをPBS１５０μＬで洗浄後、各参考例の界面活性剤溶液を２００μＬ添加した。
(4) Drug Treatment After washing the formed biofilm with 150 μL of PBS, 200 μL of the surfactant solution of each Reference Example was added.
界面活性剤添加後、各ウェルに専用のフタの突起を押し込み隙間ができないように密封してパラフィルム２枚で１周ずつ巻いた。
その上から９６ウェルプレートのフタをかぶせた後再びパラフィルム２枚で１周ずつ巻き、界面活性剤添加から５分後に超音波の照射を開始した。
After the addition of the surfactant, a projection of a dedicated lid was pushed into each well, and the well was sealed so that no gap was formed, and each parafilm was wound once around each well.
After covering the lid of the 96-well plate from above, the film was again wrapped once with two pieces of parafilm, and ultrasonic irradiation was started 5 minutes after the addition of the surfactant.
超音波処理は超音波ホモジナイザー（Qsonica社製）を用いて行い、カップホーン内の水位を１ｃｍ、出力を２０％として１０秒間の照射と５秒間の静置を４回繰り返した。
（５）バイオフィルム量の測定
界面活性剤添加から１０分後に各参考例の界面活性剤溶液２００μＬを除去して不活化PBS２００μＬで洗浄し、PBSを２００μＬ添加した。各ウェルに専用のフタの突起を押し込み隙間ができないように密封してパラフィルム２枚で１周巻いた。
The ultrasonic treatment was carried out using an ultrasonic homogenizer (manufactured by Qsonica), the water level in the cup horn was 1 cm, the output was 20%, and irradiation for 10 seconds and standing for 5 seconds were repeated 4 times.
(5) Measurement of amount of biofilm Ten minutes after the addition of the surfactant, 200 μL of the surfactant solution of each reference example was removed and washed with 200 μL of inactivated PBS, and 200 μL of PBS was added. A projection of a dedicated lid was pushed into each well, and the wells were sealed so that no gap was formed, and the parafilm was wound once with two parafilms.
その上から９６ウェルプレートのフタをかぶせ、パラフィルム２枚でそれぞれ１周ずつ巻いた。超音波ホモジナイザーのカップホーンの水位を０．５ｃｍ、出力を７０％として１０秒間の照射と５秒間の静置を４回繰り返した。 A 96-well plate was covered with a lid, and two parafilms were wrapped around each one round. With the water level of the cup horn of the ultrasonic homogenizer set to 0.5 cm and the output set to 70%, irradiation for 10 seconds and standing for 5 seconds were repeated 4 times.
照射後、フタを外して新しい９６ウェルプレートに内容物を移し、マイクロプレートリーダー（Molecular Devices社製）にてOD600の測定を行った。バイオフィルム残存率は、（界面活性剤処理時のOD600／水処理時のOD600）×100として求めた。得られた数値を表２に示す。 After irradiation, the lid was removed, the contents were transferred to a new 96-well plate, and the OD 600 was measured with a microplate reader (Molecular Devices). Biofilm residual ratio was determined as × 100 (OD 600 at OD 600 / water treatment during surfactant treatment). The obtained numerical values are shown in Table 2.
（苦味の評価）
評価パネラー４人に対して、調製した各参考例の界面活性剤溶液１０ｍＬを口に含み２０秒間洗口した後、吐き出すことにより苦味を評価した。各水溶液を口に含んでいる時の苦味及び各水溶液を口から吐き出した後の苦味を評価した。苦味は、下記の６段階の基準で評価を行い、その平均値で示した。結果を表２に示す。
０：何も感じない。
１：僅かに苦味を感じる。
２：やや苦味を感じる。
３：苦味を感じる。
４：強い苦みを感じる。
５：非常に強い苦みを感じる。
(Bitterness evaluation)
The bitterness was evaluated for four evaluation panelists by including 10 mL of the prepared surfactant solution of each reference example in their mouth, rinsing for 20 seconds, and then spit it out. The bitterness when each aqueous solution was contained in the mouth and the bitterness after each aqueous solution was exhaled from the mouth were evaluated. The bitterness was evaluated according to the following 6-level criteria, and the average value was shown. The results are shown in Table 2.
0: I don't feel anything.
1: Slight bitterness is felt.
2: A bitter taste is felt.
3: Feel bitterness.
4: I feel a strong bitterness.
5: I feel a very strong bitterness.
表２に示されるように、活性剤Ｎｏ．７０，９３，９４のベタイン系両性界面活性剤が単独でのバイオフィルム除去能が高いことが確認された。また、何れの界面活性剤も苦味を有することが確認された。 As shown in Table 2, the activator No. It was confirmed that the 70, 93, and 94 betaine amphoteric surfactants alone had high biofilm removal ability. It was also confirmed that all the surfactants had bitterness.
＜試験例１：苦味の低減試験＞
両性界面活性剤として、ラウリルジメチルアミノ酢酸ベタイン、ラウリルジアミノエチルグリシンナトリウム、Ｎ−ラウロイル−Ｎ’−カルボキシメチル−Ｎ’−ヒドロキシエチルエチレンジアミンナトリウム液、及びココアンホ酢酸Ｎａを使用し、表３〜６に示す処方で口腔用組成物を調製した。下記の各表では、口腔用組成物中の各成分を示す欄中の数値は、当該成分の含有量を示し、その単位は質量％である。また、各実施例、各比較例とも、精製水を加えることにより１００質量％となるよう調整した。
<Test Example 1: Bitterness reduction test>
As the amphoteric surfactant, betaine lauryldimethylaminoacetate, sodium lauryldiaminoethylglycine, N-lauroyl-N'-carboxymethyl-N'-hydroxyethylethylenediamine sodium solution, and sodium cocoamphoacetate are used, and shown in Tables 3 to 6. An oral composition was prepared according to the formulation shown. In each table below, the numerical value in the column showing each component in the composition for oral cavity indicates the content of the component, and the unit thereof is% by mass. Further, in each of the examples and the comparative examples, it was adjusted to be 100% by mass by adding purified water.
上記参考試験欄と同様の方法で苦味（口に含んだ時及び吐き出した後）について評価した。結果を表３〜６に示す。 The bitterness (when contained in the mouth and after vomiting) was evaluated in the same manner as in the above reference test section. The results are shown in Tables 3-6.
表３，５，６に示されるように、両性界面活性剤としてラウリルジメチルアミノ酢酸ベタイン、Ｎ−ラウロイル−Ｎ’−カルボキシメチル−Ｎ’−ヒドロキシエチルエチレンジアミンナトリウム液、及びココアンホ酢酸Ｎａを使用した場合において、グリセリンとβ−シクロデキストリンを併用した場合、苦味が効果的に低減していることが確認される。一方、表４に示されるように、アミノ酸型両性界面活性剤であるラウリルジアミノエチルグリシンナトリウムを使用した場合において、グリセリンとβ−シクロデキストリンを併用した場合であっても効果的に苦味を低減できていないことが確認される。 As shown in Tables 3, 5 and 6, when lauryldimethylaminoacetic acid betaine, N-lauroyl-N'-carboxymethyl-N'-hydroxyethylethylenediamine sodium liquid, and cocoamphoacetate Na were used as the amphoteric surfactant. In, it is confirmed that the bitterness is effectively reduced when glycerin and β-cyclodextrin are used in combination. On the other hand, as shown in Table 4, when amino acid type amphoteric surfactant sodium lauryldiaminoethylglycine sodium is used, bitterness can be effectively reduced even when glycerin and β-cyclodextrin are used in combination. It is confirmed that not.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018216224A JP2020083787A (en) | 2018-11-19 | 2018-11-19 | Composition for oral cavity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018216224A JP2020083787A (en) | 2018-11-19 | 2018-11-19 | Composition for oral cavity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2020083787A true JP2020083787A (en) | 2020-06-04 |
Family
ID=70906388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018216224A Pending JP2020083787A (en) | 2018-11-19 | 2018-11-19 | Composition for oral cavity |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2020083787A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7467173B2 (en) | 2020-03-16 | 2024-04-15 | サンスター株式会社 | Oral Composition |
| JP7467172B2 (en) | 2020-03-16 | 2024-04-15 | サンスター株式会社 | Oral Composition |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10179077A (en) * | 1996-12-20 | 1998-07-07 | Sunstar Inc | Bitter taste masking agent |
| JP2003073282A (en) * | 2001-08-31 | 2003-03-12 | Sunstar Inc | Composition for oral cavity application |
| WO2007066497A1 (en) * | 2005-12-09 | 2007-06-14 | Lion Corporation | Dentifrice composition |
| JP2010275395A (en) * | 2009-05-27 | 2010-12-09 | Kao Corp | Biofilm removing agent composition |
| JP2011068607A (en) * | 2009-09-28 | 2011-04-07 | Sunstar Inc | Composition for oral cavity |
| JP2017078029A (en) * | 2015-10-19 | 2017-04-27 | アース製薬株式会社 | Sterilization method and sterilization composition |
-
2018
- 2018-11-19 JP JP2018216224A patent/JP2020083787A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10179077A (en) * | 1996-12-20 | 1998-07-07 | Sunstar Inc | Bitter taste masking agent |
| JP2003073282A (en) * | 2001-08-31 | 2003-03-12 | Sunstar Inc | Composition for oral cavity application |
| WO2007066497A1 (en) * | 2005-12-09 | 2007-06-14 | Lion Corporation | Dentifrice composition |
| JP2010275395A (en) * | 2009-05-27 | 2010-12-09 | Kao Corp | Biofilm removing agent composition |
| JP2011068607A (en) * | 2009-09-28 | 2011-04-07 | Sunstar Inc | Composition for oral cavity |
| JP2017078029A (en) * | 2015-10-19 | 2017-04-27 | アース製薬株式会社 | Sterilization method and sterilization composition |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7467173B2 (en) | 2020-03-16 | 2024-04-15 | サンスター株式会社 | Oral Composition |
| JP7467172B2 (en) | 2020-03-16 | 2024-04-15 | サンスター株式会社 | Oral Composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103354741B (en) | Oral care composition | |
| WO2010150700A1 (en) | Dentifrice composition | |
| JP2009256228A (en) | Liquid composition for oral cavity | |
| JP2011098920A (en) | Dentifrice composition | |
| WO2003103618A1 (en) | Compositions for oral cavity | |
| JP2019116510A (en) | Oral composition | |
| WO2011055707A1 (en) | Dentifrice composition | |
| JP4873154B2 (en) | Liquid oral composition | |
| JP2006347987A (en) | Composition for oral cavity and method for enhancing foamability of composition for oral cavity | |
| JP2020083787A (en) | Composition for oral cavity | |
| JP5493732B2 (en) | Oral composition | |
| TW201034697A (en) | Dentifrice composition | |
| JP4147412B2 (en) | Oral composition | |
| JP2006347986A (en) | Composition for oral cavity | |
| JP5830324B2 (en) | Dentifrice composition | |
| KR101780837B1 (en) | Emulsion-type liquid composition for oral cavity, and process for production thereof | |
| JP2015117215A (en) | Dentifrice composition | |
| JP5051347B2 (en) | Liquid oral composition | |
| JPH11322554A (en) | Composition for oral cavity | |
| RU2524631C2 (en) | Changing of colour of chalcone-containing preparative forms for oral cavity care | |
| JP2006176416A (en) | Composition for oral cavity | |
| JP2005179290A (en) | Dentifrice composition and method for producing the same | |
| JP2013203676A (en) | Composition for oral cavity | |
| KR102642592B1 (en) | Oral composition | |
| JP5393313B2 (en) | Oral composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211015 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220624 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220705 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220831 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221115 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230111 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230404 |